詳細介紹
創(chuàng)侖供應進口Cellabs熱帶病快檢試劑盒
廣州健侖生物科技有限公司
廣州健侖長期供應各種生物原料,主要代理品牌:美國Seracare、西班牙Certest、美國Fuller、美國NOVABIOS、 Cellabs等等。
Cellabs公司是一個的生物技術公司,總部位于澳大利亞悉尼。專門研發(fā)與生產(chǎn)針對熱帶傳染性疾病的免疫診斷試劑盒。其產(chǎn)品40多個國家和地區(qū)。1998年,Cellabs收購TropBio公司,進一步鞏固其在研制熱帶傳染病、寄生蟲診斷試劑方面的位置。
創(chuàng)侖供應進口Cellabs熱帶病快檢試劑盒
該公司的Crypto/Giardia Cel IFA是國標*推薦的兩蟲檢測IFA染色試劑、Crypto Cel Antibody Reagent是UK DWI水質安全評估檢測的*抗體。
主要產(chǎn)品包括:隱孢子蟲診斷試劑,賈第蟲診斷試劑,瘧疾診斷試劑,衣原體檢測試劑,絲蟲診斷試劑,錐蟲診斷試劑等。
廣州健侖生物科技有限公司與cellabs達成代理協(xié)議,歡迎廣大用戶咨詢訂購。
我司還提供其它進口或國產(chǎn)試劑盒:登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。
歡迎咨詢
歡迎咨詢2042552662
【Seracare產(chǎn)品介紹】
貨號 | 產(chǎn)品名稱 | 產(chǎn)品描述 | 規(guī)格 | |
免疫熒光試劑盒(IFA kit) | ||||
KR1 | Crypto Cel | 隱孢子蟲(Cryptosporidium)間接免疫熒光檢測試劑 | 50 Test | |
KR2 | Crypto/Giardia Cel | 隱孢子蟲&賈第蟲(Cryptosporidium & Giardia)間接免疫熒光檢測試劑 | 50 Test | |
KG1 | Giardia Cel | 賈第蟲(Giardia)間接免疫熒光檢測試劑 | 50 Test | |
KC1 | Chlamydia Cel | 沙眼衣原體(Chlamydia trachomatis)間接免疫熒光檢測試劑 | 50 Test | |
KC2 | Chlamydia Cel LPS | 衣原體 lipopolysaccharide (LPS)間接免疫熒光檢測試劑 | 50 Test | |
KC3 | Chlamydia Cel Pn | 肺炎衣原體(Chlamydia pneumoniae)間接免疫熒光檢測試劑 | 50 Test | |
KP1 | Pneumo Cel | 卡氏肺孢子蟲(Pneumocystis carinii)間接免疫熒光檢測試劑 | 50 Test | |
KP2 | Pneumo Cel Indirect | 卡氏肺孢子蟲( Pneumocystis carinii)間接免疫熒光檢測試劑 | 50 Test | |
酶免試劑盒 ELISA kit | ||||
KG2 | Giardia CELISA | 賈第蟲(Giardia)ELISA kit | 96 Test | |
KE1 | Entamoeba CELISA Path | 溶組織內阿米巴(Entamoeba histolytica) ELISA kit | 96 Test | |
KF1 & KF2 | Filariasis CELISA | 班氏絲蟲(Wuchereria bancrofti ) ELISA kit |
| |
KM2 | Malaria Antigen (HRP2) CELISA | 惡性瘧原蟲(Plasmodium falciparum) 抗原 ELISA kit | 192 Test | |
KMC3 | Pan Malaria Antibody CELISA | 間日、三日、惡性及卵形瘧疾(Malaria)ELISA IgG kit | 192 Test | |
KT2 | T. cruzi IgG CELISA | 克氏錐蟲(Trypanosoma cruzi) ELISA IgG kit | 192 Test | |
KT3 | Toxocara IgG CELISA | 弓首線蟲(Toxocara canis) ELISA IgG kit | 192 Test | |
KF3 | Filariasis Ab (Bm14) CELISA | 淋巴絲蟲病(lymphatic filariasis) ELISA IgG kit | 480 Test | |
KM7 | Quantimal™ pLDH Malaria CELISA | 瘧疾pLDH抗體檢測 ELISA kit | 96 Test |
Severity
One-sixth of the population, that is, one billion people, is infected with one or more diseases. These diseases are not valued in the national health plan. These diseases are mainly concentrated in low-income countries in Africa and Latin America, where as many as five to seven diseases may be simultaneously prevalent in large areas of these countries. These diseases have also paid a heavy price in parts of Asia and the Middle East, but the number of overlaps is relatively small.
example
Since writing records, most of these diseases have caused catastrophes to humanity. Since the Biblical era, historical records have been full of descriptions of the pain, disability, and stigma caused by diseases such as leprosy. Some other diseases such as African sleeping sickness are notorious and have caused extremely serious clinical consequences. After the patient's brain was attacked by parasites, if the diagnosis and treatment were not timely, the mortality rate was 100%. Some diseases are not as well known, but they also have the same serious consequences. Onchocerciasis and trachoma can cause blindness. Buruli ulcers and some forms of leishmaniasis destroy soft tissues and can attack bones. Chagas disease and other forms of leishmaniasis severely damage the internal organs. Guinea worm disease caused severe pain that kept the patient bedridden for months. Lymphatic filariasis causes disability and severe swelling of the limbs and external organs of patients. Schistosomiasis and soil-borne helminths cause severe anaemia, resulting in malnutrition, affecting child development and growth.
Why are they neglected
The disease is not very eye-catching. They do not cause a large-scale outbreak and have not caught the attention of the public and the press. They have not spread internationally. Despite the enormous and long-term suffering, they did not result in the loss of a large number of people and did not affect rich countries. When developing a health agenda and budget, these diseases are often overlooked. The funds available for health investment in endemic countries are limited. These diseases must compete with more dramatic diseases that have a much higher mortality rate and cause great concern at home and abroad. Most of the pain caused by neglected tropical diseases is unknown. Patients are concentrated in remote rural areas and in the huge slums of suburban areas, without access to safe drinking water, low levels of education, poor sanitation, poor housing, and possibly no access to health care. There are other reasons why these diseases are unknown. Patients have difficulty accessing medical services, and poor families cannot afford expensive expenses. As a result, many people have been dragged to the point where they are severe enough to be unable to reverse their illness. The stigma associated with crippled and disfigured diseases makes patients, especially female patients, unwilling to seek medical attention. In the research and development field, these diseases are also ignored. There is insufficient incentive to develop new diagnostic tools, drugs, and vaccines for diseases that have a market, but patients are unable to pay for medical expenses.
Common disease
In addition to the terrestrial helminth disease affecting more than one billion people, the six most neglected tropical diseases are:
Schistosomiasis
The number of people infected is more than 200 million. About 120 million people have symptoms and about 20 million people are in serious condition.
Lymphatic filariasis
The number of infected people is about 120 million people. The disease is the second most common cause of death in the world.
Blinding trachoma
The number of infected people is about 80 million people, of whom 6 million are blind. The disease is the leading cause of blindness in the world.
Onchocerciasis
The number of infected people is about 37 million people, and the vast majority of patients are in Africa. The disease causes severe dermatitis, visual impairment or blindness, and the patient's life expectancy may be shortened by up to 15 years.
Chagas disease
The number of infected people is about 13 million, mostly concentrated in Latin America. Due to factors such as immigration, blood transfusions, congenital transmission, and organ donation, the disease has emerged in areas previously considered to be free of the disease as well as in non-endemic countries, so control and supervision work is very much needed.
Leishmaniasis
More than 12 million people are infected in 88 countries in Africa, Asia, Europe and the Americas. According to WHO estimates, 350 million people are under threat and the number of new infections each year reaches 1.5 million to 2 million. The rapidly fatal visceral leishmaniasis is the most serious form of the disease and is creating a worrying global trend.
二維碼掃一掃
【公司名稱】 廣州健侖生物科技有限公司
【】 楊永漢
【】
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化】